Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection

All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates for current interferon/ribavirin-based regimens. In this open-label, phase 3 study, 135 interferon-ineligible/int...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumada, Hiromitsu, Suzuki, Yoshiyuki, Ikeda, Kenji, Toyota, Joji, Karino, Yoshiyasu, Chayama, Kazuaki, Kawakami, Yoshiiku, Ido, Akio, Yamamoto, Kazuhide, Takaguchi, Koichi, Izumi, Namiki, Koike, Kazuhiko, Takehara, Tetsuo, Kawada, Norifumi, Sata, Michio, Miyagoshi, Hidetaka, Eley, Timothy, McPhee, Fiona, Damokosh, Andrew, Ishikawa, Hiroki, Hughes, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315868/
https://www.ncbi.nlm.nih.gov/pubmed/24604476
http://dx.doi.org/10.1002/hep.27113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315868/
https://www.ncbi.nlm.nih.gov/pubmed/24604476
http://dx.doi.org/10.1002/hep.27113

Ejemplares similares